ClinicalTrials.gg
Drug

Baricitinib clinical trials

Also written LY3009104, Olumiant and INCB 028050.

studies test it
149
open now
43
in phase 3
52
first study started
2007

How each study uses baricitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the baricitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
31 May 2018 · OLUMIANT · NDA 207924 (FDA, Drugs@FDA)
European Union
13 Feb 2017 · Olumiant · EMEA/H/C/004085 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Baricitinib
115
Baricitinib 4 MG
9
Baricitinib 4 MG Oral Tablet
6
Baricitinib 2 MG
6
Baricitinib (LY3009104) 4 mg
4

Brand

Olumiant
25

Development codes

LY3009104
56
INCB 028050
9
INCB28050
2
NCB028050
1

Studies by the year they started

148 studies that test it; most in 2020 (22); 1 more planned to start later

Studies that test baricitinib, by start year
YearStudies
20071
20091
20102
20114
20125
201310
20142
20151
20165
20174
201810
20198
202022
202110
202212
202319
202410
20255
202617

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
27
Phase 2
67
Phase 3
52
Phase 4
12
No phase
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 59 · Other 90

Eli Lilly and Company (54) · Assistance Publique - Hôpitaux de Paris (6) · Emory University (4) · Peking University People's Hospital (4) · Peking Union Medical College Hospital (3) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (3) · Tianjin Medical University General Hospital (2) · South Valley University (2)

Often tested with

Tested in the same studies.

Tocilizumab (6) · Tofacitinib (4) · Interleukin 1 Receptor Antagonist Protein (4) · Upadacitinib (3) · Dexamethasone (3) · Adalimumab (3) · Hydroxychloroquine (3) · Remdesivir (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 10, 2 in phase 3

Studies that test baricitinib, phase 3 first.

Studies

Open first, then newest update. How each study uses baricitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 149

See all 149 studies that test baricitinib →

Given beside what is tested · 5 — baricitinib is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with baricitinib

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call baricitinib · ClinicalTrials.gg INT000188

  • MeSH (NLM) C000596027baricitinibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) ISP4442I3YBARICITINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2047232Confirmed FDA, Wikidata
  • Wikidata Q4860707baricitinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C127012BaricitinibOne source FDA
  • DrugBank DB11817One source Wikidata

Also registered as baricitinib phosphate (UNII XIB47S8NNB).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.